A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-71798-x
Affiliations:
6
Authors:
11
Go to article
Institutions Authors Share
Hua Medicine (Shanghai) Co., Ltd., China
6.000000
 0.55
Peking University Third Hospital (PUTH), PKUHSC, China
3.750000
 0.34
Frontage Laboratories, Inc., United States of America (USA)
1.000000
 0.09
State Key Laboratory of Vascular Homeostasis and Remodeling, PKU, China
0.250000
 0.02
Interested in Clinical Sciences?